Results 241 to 250 of about 14,093,235 (401)

Genetically predicted KIR2DS4 mediate the association between gut microbe K10 and osteoporosis fractures: A mediation Mendelian randomization study

open access: yesPM&R, EarlyView.
Abstract Background Osteoporosis fractures pose a significant public health concern, leading to substantial morbidity and mortality rates. The emerging evidence on the potential link between gut microbiota, proteins, and osteoporosis fractures suggests a complex relationship that warrants further investigation.
Qiong Wang   +6 more
wiley   +1 more source

Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.

open access: yesJournal of Clinical Endocrinology and Metabolism, 2011
A. Burgers   +7 more
semanticscholar   +1 more source

Calycosin Targets the CYP1B1‐AKT/SP1‐GPX4 Axis to Modulate Ferroptosis in Colorectal Carcinogenesis

open access: yesPhytotherapy Research, EarlyView.
Mechanism of Calycosin in Regulating Ferroptosis in Colorectal Cancer via Binding to CYP1B1. ABSTRACT Calycosin, a natural flavonoid small‐molecule compound derived from traditional Chinese medicine, has demonstrated remarkable pharmacological activity in the field of cancer therapy.
Lihan Bie   +9 more
wiley   +1 more source

Microglia-mediated IGF-I neuroprotection in the rd10 mouse model of retinitis pigmentosa.

open access: yesInvestigative Ophthalmology and Visual Science, 2011
A. Arroba   +3 more
semanticscholar   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours [PDF]

open access: hybrid, 2014
Breelyn A. Wilky   +13 more
openalex   +1 more source

Home - About - Disclaimer - Privacy